Oxford Biomedica PLC Oxford BioMedica plc Director's Share Purchase (3739Y)
December 01 2014 - 2:00AM
UK Regulatory
TIDMOXB
RNS Number : 3739Y
Oxford Biomedica PLC
01 December 2014
Oxford BioMedica plc Director's Share Purchase
Oxford, UK - 1 December 2014: Oxford BioMedica plc ("Oxford
BioMedica" or "the Company") (LSE: OXB), a leading gene and cell
therapy company, was informed that on 28 November 2014 one of its
Directors acquired ordinary shares of 1p each ("Ordinary Shares")
as follows:
Interest after purchase
Director / Title Price per Number of Ordinary Number of % of total
PDMR share (p) Shares acquired Ordinary issued share
on Shares capital
28 November 2014
Andrew Heath Non-Executive 4.932p 150,000 1,000,000 0.04%
The issued share capital of the Company is 2,565,470,169 1p
ordinary shares.
-Ends-
For further information, please contact:
Oxford BioMedica plc:
John Dawson, Chief Executive Officer Tel: +44 (0)1865
Tim Watts, Chief Financial Officer 783 000
Media Enquiries:
Mary-Jane Elliott/Matthew Neal/Laura Thornton Tel: +44 (0)20
Consilium Strategic Communications 7309 5700
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell
therapy company with an unrivalled portfolio of gene therapy
products in development and a platform of exclusive and pioneering
technologies with which it designs, develops and manufactures
unique gene-based medicines for some of world's largest
pharmaceutical companies. Leveraging its proprietary LentiVector(R)
IP and gene delivery system technology platform and unique tumour
antigen (5T4), Oxford BioMedica is advancing its pipeline of seven
gene therapy products addressing diseases for which there are
currently no treatments or that are inadequately treated today,
including ocular and central nervous system disorders. OXB
Solutions, the Company's industry-leading manufacturing and
development business, provides services to collaborators and
partners working in gene and cell therapy, including Novartis and
Immune Design Corp. In addition, the Company has licenced products
and IP to Sanofi, Pfizer, MolMed, Sigma-Aldrich, Biogen Idec,
Emergent BioSolutions and ImaginAb. Further information is
available at www.oxfordbiomedica.co.uk and
www.oxbsolutions.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSBLBDBBBDBGSI
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Sep 2023 to Sep 2024